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Estimates of Mortality Benefit From Ideal Cardiovascular Health
Metrics: A Dose Response Meta-Analysis
Ehimen C. Aneni, MD, MPH; Alessio Crippa, MS, PhD(c); Chukwuemeka U. Osondu, MD, MPH; Javier Valero-Elizondo, MD, MPH;
Adnan Younus, MD; Khurram Nasir, MD, MPH; Emir Veledar, PhD
Background-—Several studies have shown an inverse relationship between ideal cardiovascular health (CVH) and mortality.
However, there are no studies that pool these data to show the shape of the relationship and quantify the mortality benefit from
ideal CVH.
Methods and Results-—We conducted a systematic internet literature search of multiple databases including MEDLINE, Web of
Science, Embase, CINAHL, and Scopus for longitudinal studies assessing the relationship between ideal CVH and mortality in
adults, published between January 1, 2010, and May 31, 2017. We included studies that assessed the relationship between ideal
CVH and mortality in populations that were initially free of cardiovascular disease. We conducted a dose-response meta-analysis
generating both study-specific and pooled trends from the correlated log hazard ratio estimates of mortality across categories of
ideal CVH metrics. A total of 6 studies were included in the meta-analysis. All of the studies indicated a linear decrease in
(cardiovascular disease and all-cause) mortality with increasing ideal CVH metrics. Overall, each unit increase in CVH metrics was
associated with a pooled hazard ratio for cardiovascular disease mortality of 0.81 (95% confidence interval, 0.75–0.87), while each
unit increase in ideal CVH metrics was associated with a pooled hazard ratio of 0.89 (95% confidence interval, 0.86–0.93) for all-
cause mortality.
Conclusions-—Our meta-analysis showed a strong inverse linear dose-response relationship between ideal CVH metrics and both
all-cause and cardiovascular disease–related mortality. This study suggests that even modest improvements in CVH is associated
with substantial mortality benefit, thus providing a strong public health message advocating for even the smallest improvements in
lifestyle. ( J Am Heart Assoc. 2017;6:e006904. DOI: 10.1161/JAHA.117.006904.)
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C ardiovascular health (CVH), as defined in the 2010American Heart Association’s national goal,1 describes a
construct of 7 health metrics, each of which is classified into
levels as poor, intermediate, and ideal. Researchers have
often represented these metrics as numeric scores in order to
categorize CVH based on the number of ideal CVH metrics
achieved. Many studies have defined ideal CVH as the
presence of as few as 5 and as many as 7 ideal CVH
metrics.2,3
There is increasing evidence of the benefits of achieving
ideal CVH in the primary prevention of cardiovascular disease
(CVD), mortality, and non-CVD outcomes such as cancer and
depression.4 However, the prevalence of ideal CVH in US and
non-US populations is low, ranging from 0.5% to 12%.4
Studies on ideal CVH have shown a fairly consistent
inverse association with CVD and all-cause mortality.2,3,5–8
However, the shape and the pooled strength of the associ-
ation remains unknown. A previous meta-analysis compared
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high versus low numeric CVH scores and showed an inverse
relationship between higher numbers of ideal CVH metrics
and mortality.9 The limitation of this approach is that such an
analysis ignores the shape (linear or otherwise) of the
association and does not estimate mortality benefit associ-
ated with per-unit increases in ideal CVH metrics. Therefore,
we conducted a dose-response meta-analysis to quantify and
examine the shape of the association between an increasing
number of ideal CVH metrics and mortality.
Methods
We conducted an internet literature search of multiple
databases—MEDLINE database using PubMed and OvidSP
interfaces, Web of Science, Embase, CINAHL and Scopus—for
studies on the association of ideal CVH and mortality. We
combined search words such as “ideal cardiovascular health,”
“cardiovascular health metrics,” and “life’s simple seven” with
“mortality,” “cardiovascular mortality,” and “cardiovascular
death.” We included studies published from January 1, 2010,
to March 31, 2017.
To be included in the meta-analysis, studies had to be
longitudinal, have assessed the relationship between ideal
CVH (using the American Heart Association definition) and
mortality in a population aged 18 years and older that was
initially free of CVD, and be published in English.
Data were manually extracted from the articles to an Excel
spreadsheet. Information extracted included first author
name, publication date, study date, follow-up period, age
range, sex distribution, comparison groups, total population at
baseline, total mortality and mortality in each comparison
group at baseline, hazard ratios (HRs) and confidence
intervals for exposure group, and covariates that were
Table. Description of Studies Included in the Meta-Analysis
Study
Patients,
No. Country/Cohort Date of Study
Mean Age or
Age Range, y
Women,
% Adjustments
Comparison
Groups
Referent
CVH Metric
Categories
Yang, 20122 15 305 United States/NHANES 1988–2010 20–80+ 51.8 Age, sex, and
race-ethnicity
6 0 to 1
Artero, 20123 11 993 United States/ACLS 1987–1999 20–88 24.3 Age, sex, examination
year, alcohol, and
family history of CVD
3 0 to 2
Ford, 20125 7622 United States/NHANES 1999–2002 Mean, 43 52 Age, sex, race-ethnicity,
education,
self-reported health
status, health insurance,
alcohol, and
cancer history
6 0
Liu, 20146 91 698 China/KaiLuan Study 2006–2007 18–98 21 Age, sex, income,
education, alcohol,
previous MI, stroke,
and cancer
5 0 to 1
Kim, 20127 12 538 Korea/Seoul Male
Cohort Study
1993 40–59 0 Age, education, alcohol,
and family history of CVD
5 0 to 2
Dong, 20128 2981 United States/NOMAS 1993–2001 Mean, 69 63.7 Age, sex, and race-ethnicity 5 0 to 1
ACLS indicates Aerobics Center Longitudinal Study; CVD, cardiovascular disease; CVH, cardiovascular health; MI, myocardial infarction; NHANES, National Health and Nutrition
Examination Survey; NOMAS, Northern Manhattan Study.
Clinical Perspective
What Is New?
• Employing a dose-response meta-analytic approach, the risk
of mortality was quantified for each unit change in ideal
cardiovascular health metrics.
• A linear inverse relationship exists between increasing
number of ideal cardiovascular health and both cardiovas-
cular disease and all-cause mortality.
What Are the Clinical Implications?
• The study findings suggest that there is life-saving benefit
associated with improving cardiovascular health by as little
as one ideal cardiovascular health metric.
• This information is clinically relevant and useful for conver-
sations with patients on the benefits of cardiovascular
health.
DOI: 10.1161/JAHA.117.006904 Journal of the American Heart Association 2
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adjusted for in regression models. For each study, CVH
categories were assigned to their corresponding HR estimate.
Where categories were greater than a single CVH metric, the
midpoint between the upper and lower boundary for that
category was used.
Using methods described by Greenland and Longnecker10
and Orsini et al,11 we estimated the trend from the
correlated log HR estimates of mortality across categories
of ideal CVH metrics. We investigated a potential nonlinear
relationship using restricted cubic splines with 3 knots
located at the 10th, 50th, and 90th percentiles of the
exposure distribution. These cubic spline knots correspond
to values 0.5, 3, and 6 in the 7-point ideal CVH score scale.
We assumed that the curves were linear below the first and
above the last knot.
A random-effects meta-analysis was used to account for
the heterogeneity across studies. Statistical heterogeneity
between studies was further evaluated using I2 statistics.12
Publication bias was evaluated with the use of the Egger
regression asymmetry test.13 P<0.05 was considered
statistically significant. All statistical analyses were per-
formed in R statistical software14 using the dosresmeta
package.15
Results
The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) flow chart (Figure S1) details the
search results. In total, 6 studies with a combined population
of 142 137 participants met the study’s inclusion crite-
ria.2,3,5–8 Details of the individual studies are shown in the
Table and Table S1.
The spaghetti plots shown in Figure 1A and 1C show the
study-specific HRs as a function of the ideal CVH metrics for
CVD and all-cause mortality. The general appearance of these
plots shows that the HRs decreased as the number of ideal
CVH components increased. However, the study by Ford
et al5 appeared visually distinct from the others in that it had
a rapid decline in the risk of mortality and thereafter
plateaued. This was more prominent in the CVD mortality plot.
The test of nonlinearity was not statistically significant for
both CVD mortality (P=0.26) and for all-cause mortality
(P=0.64), suggesting that the difference in the shape of the
curves (between Ford et al and the other 5 studies) may have
been caused by chance. As such, a linear model was adopted
for both analyses. The estimated linear trends for the
individual studies and the pooled estimates are shown in
Figure 1. A and C, Spaghetti plot showing the association of ideal cardiovascular health (CVH) with
(A) cardiovascular disease (CVD) and (C) all-cause mortality in the included studies. B and D, Estimated
linear trends of showing association of ideal CVH with (B) CVD mortality and (D) all-cause mortality in
the included studies. Solid lines represent linear trend, dashes represent confidence intervals, and
dotted lines represent cubine splines.
DOI: 10.1161/JAHA.117.006904 Journal of the American Heart Association 3
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Figures 1B and 1D and 2 for CVD and all-cause mortality,
respectively.
Overall, each unit increase in CVH metrics was associated
with a pooled HR for CVD mortality of 0.81 (95% confidence
interval, 0.75–0.87) with moderate heterogeneity (I2=66%,
P=0.02; Figure 2A). For all-cause mortality, each unit increase
in ideal CVH metrics was associated with a pooled HR of 0.89
(95% confidence interval, 0.86–0.93) with moderate
Figure 2. Forest plot showing results of meta-analysis of studies on the relationship between ideal
cardiovascular health (CVH) and (A) cardiovascular disease (CVD) and (B) all-cause mortality.
DOI: 10.1161/JAHA.117.006904 Journal of the American Heart Association 4
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heterogeneity (I2=72%, P=0.003; Figure 2B). There was no
evidence of publication bias (Egger test, P=0.17 for CVD
mortality and 0.63 for all-cause mortality).
In the sensitivity analyses excluding the results from Ford
et al, there was no substantial difference in the pooled HRs
(Figure 2).
Discussion
In this dose-response meta-analysis of 6 studies with over
140 000 participants, we observed an inverse linear relation-
ship between ideal CVH metrics and mortality. For each
additional ideal CVH metric a person has, we estimated a 19%
reduction in mortality from CVD and 11% decline in the risk of
all-cause mortality.
In addition to confirming the findings of previous individual
longitudinal studies that showed a net mortality benefit from
ideal CVH, the present meta-analysis also shows that even
small improvements in CVH, such as achieving only one
additional ideal CVH metric, is associated with significant
reduction in death. Furthermore, findings from this meta-
analysis suggest a linear dose-response relationship between
ideal CVH and mortality reduction, supporting a possible
causal link between the 2 entities.
The dose-response methodology employed in this meta-
analysis has the advantage of quantifying per-unit risk. This
technique also takes into account the individual HRs from
studies thus preserving the control for confounders con-
ducted in the individual studies. It also circumvents the
difficulties in conducting a conventional meta-analysis at
instances in which there are multiple levels of exposure. The
use of restricted cubic spline analysis allows for observing the
mortality decline with each unit increase in ideal CVH metric.
Interestingly, as shown in Figure 1, there was minimal
difference between the cubic spline and linear trend graphs.
This is the first study to show a dose-response relationship
between ideal CVH metrics and mortality reduction.
Study Limitations
Our study is limited by significant heterogeneity between the
studies. The source of this heterogeneity is unclear;
however, the results of our sensitivity analysis that excluded
the work of Ford et al showed no substantial change in our
findings. Because of the small number of studies, we were
limited in our ability to conduct stratified analysis, and we
were also unable to conduct a meta-regression analysis.
There is some variability in the levels of CVH metrics that
were considered in the different studies; however, the range
of exposures is similar across studies with the minimum of 0
to 1 and a maximum of 6 to 6.5. Thus, all studies
contributed in determining the pooled association at the
extremes of CVH metrics (≤1 and ≥6). None of the studies
included in this meta-analysis assessed the impact of
intermediate ideal CVH metrics on mortality and as such
we were limited in our ability to assess intermediate levels
of CVH and mortality on an aggregate basis. We were also
limited by the shortcomings of the individual studies such as
their lack of repeated exposure assessment and the varying
follow-up periods.
While unable to predict the effort required by individuals at
various levels of CVH to effect improvements in their CVH
status, the findings of this study suggest that there is life-
saving benefit associated with improving CVH by as little as
one ideal CVH metric. More is needed to better understand
which individual metrics have the greatest impact on mortality
in the setting of CVH.
Conclusions
Our meta-analysis of 6 individual longitudinal studies shows a
strong inverse linear dose-response relationship of ideal CVH
with mortality. This study’s findings suggest that even modest
improvements in CVH is associated with substantial mortality
benefit, thus providing a strong public health message
emphasizing the benefits of incremental improvements in
lifestyle.
Disclosures
None.
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Table S1. Additional description of studies included in the meta-analysis. 
 
*Exposure level corresponds to number of ideal CVH metrics or the median when it is a range of metrics. 
CVH Cardiovascular Health; CVD Cardiovascular Disease 
 
 
First Author, Year Number of 
Ideal CVH 
Metrics 
Exposure 
Level* 
CVD Mortality All-Cause Mortality 
Cases N Cases N 
Yang, 20121 
 
0 – 1 0.5 183 1236 405 1236 
2 2 303 2608 723 2608 
3 3 300 3370 760 3370 
4 4 201 3081 490 3081 
5 5 77 2060 226 2060 
6 – 7 6.5 21 957 69 957 
Artero, 20122 
 
 
0 – 2 1 45 4675 145 4675 
3 – 4 3.5 20 5116 123 5116 
5 – 7 6 5 2202 37 2202 
Ford, 20123 
 
0 0 7 111 10 111 
1 1 13 675 57 675 
2 2 26 1468 104 1468 
3 3 27 1900 104 1900 
4 4 13 1497 49 1497 
5 – 7 6 4 1204 15 1204 
Liu, 20144 
 
0 – 1 0.5 75 12882 223 12882 
2 2 133 22776 430 22776 
3 3 142 28003 492 28003 
4 4 83 19684 328 19684 
5 – 7 6 25 8353 91 8353 
Ji Young Kim, 20135 
 
0 – 2 1 21 695 87 695 
3 3 50 2229 246 2229 
4 4 60 4231 371 4231 
5 5 36 3932 284 3932 
6 – 7 6.5 4 1451 66 1451 
Dong, 20126 
 
0 – 1 0.5 95 566 211 566 
2 2 127 953 344 953 
3 3 136 906 342 906 
4 4 59 426 178 426 
5 – 7 6 18 131 48 131 
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Studies identified through database searching
(Pubmed, Embase, Web of Science, CINAHL and Scopus)
(n = 539)
Abstracts screened
(n= 135)
Full-text articles assessed for 
eligibility
(n = 11 )
Studies included in 
quantitative synthesis (meta-
analysis)
(n = 6 )
Full-text articles excluded, 
(n = 5, no mortality 
assessment)
Did not meet eligibility 
criteria
(n = 124)
Total Records after removal 
of duplicates
(n =242)
Papers excluded after 
scanning titles
(n=107)
Figure S1. PRISMA flow chart 
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